News >

Novel Regimens Take Precedence in Newly Diagnosed CLL

Caroline Seymour
Published: Monday, Mar 11, 2019

Matthew S. Davids, MD

Matthew S. Davids, MD, MMSc
With the introduction of novel therapies in newly diagnosed chronic lymphocytic leukemia (CLL), physicians may be moving away from historically predominant chemoimmunotherapy-based treatment approaches towards novel, fixed-duration strategies, explained Matthew S. Davids, MD, MMSc.

One such strategy is exploring the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with treatment-naïve CLL who have coexisting medical conditions. In the phase III CLL14 trial, patients were randomized to receive either 12 months of venetoclax and 6 months of obinutuzumab or 6 months of obinutuzumab followed by 6 months of chlorambucil.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication